MECHANISMS OF ARRHYTHMOGENESIS
Cardiac arrhythmias arise as a result of abnormal impulse initiation or conduction. For better understanding of the fundamental mechanisms of arrhythmia formation, a brief review of the ionic currents underlying the genesis of the cardiac action potential is warranted.
The cardiac action potential represents the rapid flux of ions across the cell membrane of excitable tissue. The resultant depolarization travels across the heart and produces a wavefront of excitation. Figure 1 summarizes the ionic currents involved in the genesis of the cardiac action potential. At baseline, a resting potential of Ϫ80 to Ϫ90 mV is maintained as a result of a high level of potassium channel conductance. Phase 0 is the result of activation of fast sodium channels, phase 1 results from the transient outward potassium current, phase 2 (the plateau) results from a balance of inward (sodium and calcium) and outward (potassium) currents, and phase 3 (repolarization) results mainly from the delayed activation of potassium channels. In some cells, such as in the sinoatrial node and the atrioventricular node, repolarization is followed by spontaneous, gradual depolarization (phase 4) leading to another action potential. This process is called normal automaticity.
Independent of the relative importance of the pathologic substrate vs. the altered milieu, three fundamental electrophysiologic mechanisms are responsible for arrhythmia formation. These are reentry, abnormal automaticity, and triggered activity.
Reentry is the most common mechanism of arrhythmia formation. It results when a wavefront of excitation propagates in one direction while blocking in an adjacent direction, subsequently returns to the blocked area, and successfully excites this region leading to continuous electrical activation rather than being extinguished. The following three conditions are typically necessary for reentry to occur: the presence of a substrate in which a central area of inexcitable tissue separates two pathways for conduction; unidirectional block in one of the two pathways; and slow conduction permitting delay and recovery of excitability in the previously blocked area. These conditions may be anatomically defined, as in the tissue surrounding an infarct zone, or may be the result of functional alterations in conduction secondary to electrolyte disturbances or ischemia. Thus, patients in whom some, but not all, of the criteria necessary for reentrant arrhythmias are present may not develop any arrhythmias until exposed to factors producing changes in refractoriness or conduction.
Abnormal automaticity refers to the development of spontaneous, phase 4 depolarization and impulse formation in cells that otherwise do not exhibit automatic pacemaker activity. Normally contracting ventricular myocytes typically do not have spontaneous pacemaker activity, but under certain conditions these cells may develop a "leakage current" during phase 4, resulting in impulse formation. Ischemia can lead to this phenomenon (1), and diseased cardiac tissue is particularly susceptible to developing abnormal pacemaker activity. Abnormal automaticity, distinguished from normal automaticity, causes repetitive depolarization at rates faster than that found in normally automatic tissues, resulting in overdrive suppression of the sinoatrial node (2) . Automatic cells in the atrioventricular node or His-Purkinje system may also usurp the sinus node pacemaker activity by a process called enhanced automaticity, in which phase 4 depolarization becomes accelerated by drugs, sympathetic activity, or metabolic disturbances.
Triggered activity refers to abnormal impulse formation from afterdepolarizations. Afterdepolarizations, which can be either early or delayed, are oscillations of membrane potential occurring during or immediately after repolarization ( Fig. 1 ). Early afterdepolarizations are important in the genesis of torsades de pointes. The mechanism of early afterdepolarizations appears to be related to delayed reactivation of ion channels that carry inward depolarizing currents. These channels are responsible for the plateau phase of the action potential and normally become inactive during early repolarization (phase 3). When the action potential duration is prolonged, these channels may reopen, resulting in a net inward flow of ions. The result is positive oscillations called early afterdepolarizations. If early afterdepolarizations are of sufficient amplitude to reach threshold, abnormal impulse propagation is triggered. Therefore, the presence of early afterdepolarizations is favored by conditions that prolong action potential duration (a prolonged QT interval on the electrocardiogram), such as slow heart rates (action potential duration is inversely related to heart rate), antiarrhythmic drugs (quinidine, procainamide, and sotalol), and electrolyte disturbances, such as hypokalemia, hypocalcemia, and hypomagnesemia. On the other hand, delayed afterdepolarizations result from increased intracellular calcium levels. Thus, conditions that lead to arrhythmia formation from delayed afterdepolarization-induced triggered activity are generally associated with an increase in intracellular calcium. The classic example is digitalis intoxication. Digitalis inhibits the Na ϩ /K ϩ pump resulting in increased intracellular Na ϩ that, in turn, results in increased levels of Ca 2ϩ via the Na ϩ /Ca 2ϩ exchanger. Other causes of delayed afterdepolarizations and triggered arrhythmias are catecholamines and increases in heart rate (2) . Ischemia also results in intracellular calcium overload and has been implicated as a cause of triggered arrhythmias (3).
EFFECTS OF METABOLIC DISTURBANCES AND ISCHEMIA ON ARRHYTHMOGENESIS
Metabolic disturbances and ischemia are common findings in the critically ill patient. Their influences on arrhythmogenesis are complex and not necessarily predicted by Nernst-Goldman equilibrium or by experimental findings from in vitro preparations. This is a result of concomitant alterations in ion channel conductance, effects on membrane ion exchangers, and synergistic or opposing effects of more than one abnormality. Nonetheless, a brief review of the electrophysiologic effects of these disorders helps the clinician appreciate the importance of these potentially modifiable factors in the ICU.
Metabolic Disturbances
The clinical features of rhythm disorders associated with specific electrolyte abnormalities are well known to most readers. Therefore, we will limit our dis-cussion to the electrophysiologic basis underlying arrhythmogenesis during changes in potassium, calcium, and magnesium levels.
Potassium. Hypokalemia, as predicted by the Nernst equation, hyperpolarizes the resting membrane potential to more negative values, and consequently may cause slowing of conduction (4, 5) . In addition, hypokalemia decreases potassium conductance and may enhance automaticity (4 -7). However, the most important effect of hypokalemia is a delay in repolarization and prolongation of the action potential duration which may lead to early afterdepolarization formation and triggered arrhythmias. Hyperkalemia, on the other hand, has two major effects. First, it increases the permeability to potassium (5, 8) , and second, it shifts the cell membrane resting potential to a less negative value. The result is shortening of the action potential duration, suppression of automaticity, and slowing of conduction. (4, 5, 9) . At extremes of hyperkalemia, marked QRS widening (sine wave) is observed. Severe hyperkalemia requires prompt correction because its cardiac effects may be lethal. In the management of critically ill patients, it is our opinion that maintenance of high normal values of K ϩ is reasonable in view of its effects on action potential duration shortening, the prevention of early afterdepolarizations, and suppression of enhanced automaticity.
Calcium and Magnesium. Hypocalcemia causes QT c prolongation and thus, may result in early afterdepolarizations and triggered arrhythmias. Prolongation of the QT c secondary to acute hypocalcemia is a potential cause of torsades de pointes (10), although much less commonly than with hypokalemia or hypomagnesemia (11) . On the other hand, hypercalcemia causes QT c shortening. Although excess intracellular calcium caused by digitalis toxicity, catecholamines, or ischemia can cause delayed afterdepolarizations and triggered arrhythmias, increased extracellular calcium concentration does not result in triggered arrhythmias (4, 12) . Hypomagnesemia, although rarely an isolated disorder, is also associated with prolongation of the QT c interval and torsades de pointes. Hypermagnesemia, on the other hand, is not usually associated with clinical arrhythmias, although slowing of the AV node and ventricular conduction may be seen (4) . Calcium and magnesium are important primarily for their interaction Figure 1 . Summary of the ionic currents involved in the genesis of the cardiac action potential. EAD, early afterdepolarization; DAD, delayed afterdepolarization; baseline, Ϫ80 mV; phase 0, activation of fast sodium channels; phase 1, transient outward potassium current; phase 2, the plateau; phase 3, repolarization; phase 4, spontaneous, gradual depolarization. with other ions. Calcium is used to treat life-threatening hyperkalemia, and its effect is thought to be because of the resting membrane potential shifting to more negative values (5) . Similarly, Mg 2ϩ is used to treat torsades de pointes primarily by shortening action potential duration and suppressing early afterdepolarizations (13) . It should also be noted that magnesium and potassium deficits often coexist making Mg 2ϩ repletion particularly important in the management of hypokalemia.
Ischemia
Myocardial ischemia occurring in the ICU, either from underlying coronary artery disease or from hemodynamic and hypoxic stress, can produce a multitude of electrophysiologic effects. These include partial depolarization of the resting membrane potential resulting in inactivation of the fast sodium channels and slowing of conduction, increased intracellular calcium, elevation of extracellular potassium, and prolongation of refractoriness despite shortening of the action potential duration (14) . The resulting effects on arrhythmogenesis are complex. Abnormal automaticity, triggered activity, and reentry can all result from these perturbations.
Miscellaneous
In addition to electrolyte shifts and ischemia, other systemic influences found in the critically ill patient, such as acid-base abnormalities, hypoxia, and enhanced catecholamine levels can also predispose to ventricular arrhythmias (14) . The role of the sympathetic nervous system in arrhythmogenesis cannot be overemphasized. Through stimulation of the ␤-adrenergic receptor, sympathetic activation or exogenous catecholamines can result in enhanced automaticity or triggered activity. Reentry may also be facilitated, particularly in the presence of ischemia.
APPROACH TO VENTRICULAR ARRHYTHMIAS IN THE CRITICALLY ILL PATIENT
A few general principles regarding the evaluation of ventricular arrhythmias in the ICU deserve mention. Newly observed arrhythmias warrant an assessment of electrolytes, acid-base and oxygenation status, and a 12-lead electrocardiogram with par-ticular attention to the QT c interval. The position of intravascular catheters should be evaluated, because occasionally, dislodgment can result in mechanically-induced arrhythmias. Prolongation of the QT c interval should prompt a search for potential causes, if not already apparent. Specific attention should be given to the morphologic characteristics of the tachycardia, and it should be emphasized that polymorphic ventricular tachycardia can be mistakenly labeled as monomorphic when observed in a few leads only. Routine assessment of cardiac enzymes is not mandatory with the onset of every arrhythmia, but should be guided by the clinical setting and the type of arrhythmia. For example, polymorphic ventricular tachycardia in the setting of a normal QT c interval is often the result of ischemia, whereas monomorphic ventricular tachycardia usually results from a fixed substrate (a scar) and rarely mandates a search for acute ischemia.
Another general problem commonly encountered in the ICU setting is the management of inotropic and vasoactive support in patients with ventricular arrhythmias. As previously discussed, catecholamines are an important component in the development of many arrhythmias, and consequently, a reduction or elimination of this factor is often helpful in the treatment of ventricular arrhythmias. On the other hand, arrhythmias resulting from decompensated heart failure may indeed subside with appropriately tailored hemodynamic therapy. Quite often, optimization of the hemodynamic status takes priority, and antiarrhythmic drug therapy may be required to treat symptomatic ventricular arrhythmias in the setting of continued inotropic and vasoactive support.
In the following section, we will discuss both acute and long-term evaluation and management of patients with ventricular arrhythmias. In the first part, we will discuss the approach to ventricular ectopy and monomorphic ventricular tachycardia. In the second part, we will review the approach to polymorphic ventricular tachycardia.
Ventricular Ectopy and Monomorphic Ventricular Tachycardia
Premature Ventricular Complexes. Premature ventricular complexes can result from any of the previously described mechanisms: reentry, abnormal automaticity, or triggered activity. They are iden-tified electrocardiographically by a wide QRS complex (Ͼ120 msec), but must be distinguished from supraventricular beats conducted aberrantly. A general evaluation including electrolyte measurements and a 12-lead electrocardiogram is indicated. However, unless the ectopy is associated with hemodynamic impairment, suppressive therapy and a reduction of inotropic or vasopressor support is rarely warranted. The long-term management of patients with premature ventricular complexes is guided by the same principles and rarely involves antiarrhythmic drug therapy.
Nonsustained Monomorphic Ventricular Tachycardia. Nonsustained monomorphic ventricular tachycardia may be caused by reentry, abnormal automaticity, or triggered activity. As stated for premature ventricular complexes, a limited evaluation is typically all that is required, and therapy is rarely necessary in the absence of symptoms or hemodynamic compromise. Again, withdrawal of vasopressors as tolerated in addition to correction of metabolic disturbances (particularly hypokalemia) may decrease the frequency and duration of nonsustained monomorphic ventricular tachycardia. Although the presence of nonsustained monomorphic ventricular tachycardia in the ICU has little immediate importance, it provides an opportunity to identify a potentially high risk group of patients amenable to primary prevention. In general, the long-term significance of nonsustained monomorphic ventricular tachycardia is related to the presence and severity of underlying structural heart disease. Indeed, in the absence of a reversible cause (electrolyte abnormality, recent myocardial infarction) patients with nonsustained monomorphic ventricular tachycardia, coronary artery disease, and decreased left ventricular ejection fraction (Յ0.40) are at high risk for sudden cardiac death. Given the limited positive predictive value of even the best clinical variables, electrophysiologic testing provides an additional tool for risk stratification. Patients with inducible arrhythmias benefit from an implantable cardioverterdefibrillator (15, 16) . Therefore, after recovery from acute illness, patients with persistent, nonsustained monomorphic ventricular tachycardia who also have coronary artery disease and an ejection fraction Յ0.40 should be evaluated with an electrophysiology study. If sustained arrhythmias are inducible, a cardio-verter-defibrillator should be implanted because it is superior to antiarrhythmic therapy in reducing total mortality (Fig.  2) . The evaluation of nonsustained monomorphic ventricular tachycardia in patients with nonischemic cardiomyopathy is less clear. Although patients with nonischemic cardiomyopathy are at increased risk for sudden death, it is not known whether the presence of nonsustained monomorphic ventricular tachycardia is an additive risk factor. Furthermore, electrophysiology study is limited by poor sensitivity and specificity in this patient population. Therefore, in patients with nonischemic cardiomyopathy, we recommend no treatment for nonsustained monomorphic ventricular tachycardia unless the patient is symptomatic. In the presence of symptoms, ␤ blocker therapy should be started as tolerated. When symptoms persist, amiodarone may be initiated because this antiarrhythmic drug is at least safe (neutral mortality effect) (17) in this patient population and was found to provide a survival benefit in one study (18) . Ongoing randomized trials may provide insight on the best management strategy in these patients (19) . Finally, in the absence of structural heart disease, nonsustained monomorphic ventricular tachycardia carries no added long-term risk, and therapy is required only for debilitating symptoms.
Sustained Monomorphic Ventricular Tachycardia. The most common mechanism underlying sustained monomorphic ventricular tachycardia is reentry. Sus-tained monomorphic ventricular tachycardia occurs almost exclusively in patients with underlying structural heart disease, most commonly, coronary artery disease or dilated cardiomyopathy. The substrate for reentry is typically the border zone of a healed myocardial infarction. Sustained monomorphic ventricular tachycardia frequently recurs, and the prognosis in the setting of left ventricular systolic dysfunction is poor. Although certain factors, such as acute infarction and metabolic disturbances, may trigger sustained monomorphic ventricular tachycardia, it should be emphasized that even with the elimination of potentially reversible causes, recurrence rates may remain high because of the presence of a fixed substrate. Indeed, a recent study (20) suggested that patients developing sustained monomorphic ventricular tachycardia in the early phase of acute myocardial infarction (MI) remain at high risk after hospital discharge.
The acute management of sustained monomorphic ventricular tachycardia is relatively straightforward. Hemodynamically unstable or symptomatic sustained monomorphic ventricular tachycardia requires prompt, unsynchronized cardioversion. Stable or recurrent sustained monomorphic ventricular tachycardia can be treated with lidocaine, procainamide, or amiodarone. Termination of sustained monomorphic ventricular tachycardia with antitachycardia pacing is also an option and should be considered in patients with transvenous or epi-cardial pacing wires, permanent pacemakers, or implantable cardioverterdefibrillators through which rapid pacing may be readily achieved with a stimulator or programmer. However, the potential for tachycardia acceleration should always be kept in mind, and an external defibrillator should be readily available.
Until recently, the long-term management of patients with sustained monomorphic ventricular tachycardia was not clear because a direct comparison of the effects on total mortality of drug therapy and implantation of a cardioverterdefibrillator was not available. Today, several randomized, controlled trials have demonstrated the superiority of implantable cardioverter-defibrillator therapy in improving survival in patients with sustained ventricular arrhythmias. The Antiarrhythmics Versus Implantable Defibrillator Trial, the Canadian Implantable Defibrillator Study, and the Cardiac Arrest Study in Hamburg evaluated the efficacy of implantable cardioverterdefibrillator therapy vs. drug therapy (usually amiodarone) in survivors of cardiac arrest and in patients with sustained monomorphic ventricular tachycardia associated with hemodynamic impairment (21) (22) (23) . Therapy with an implantable cardioverter-defibrillator was found to be superior to drug therapy in both the Antiarrhythmics Versus Implantable Defibrillator Trial and Canadian Implantable Defibrillator Study, although the difference did not reach statistical significance in the Canadian Implantable Defibrillator Study. Preliminary results from the Cardiac Arrest Study in Hamburg trial further support the use of implantable cardioverter-defibrillators as primary therapy in survivors of near-fatal ventricular arrhythmias (24) . Based on these results, we recommend that in the absence of a reversible cause, patients with sustained monomorphic ventricular tachycardia associated with syncope or left ventricular systolic dysfunction (ejection fraction Յ0.40) receive an implantable cardioverter-defibrillator (Fig. 2) . In the setting of reversible causes, such as acute infarction or metabolic abnormalities, no specific guidelines exist for long-term management because these trials specifically excluded such patients. Because the substrate for sustained monomorphic ventricular tachycardia may persist after correcting reversible factors, it is our recommendation that these patients undergo an electrophysiology study after the resolution of the acute illness. Com- bined with an assessment of the underlying structural heart disease, the results of the electrophysiology study should help guide plans for long-term treatment. Until more data become available from controlled trials, we believe that this approach takes into consideration both the clinical setting surrounding the arrhythmia, as well as the potential presence of a permanent substrate (Fig. 2 ).
Polymorphic Ventricular Tachycardia
Polymorphic ventricular tachycardia commonly degenerates to ventricular fibrillation, and these arrhythmias are approached similarly. Sustained polymorphic ventricular tachycardia is invariably symptomatic and requires prompt, unsynchronized, direct current cardioversion. After restoration of sinus rhythm, the first step should be the evaluation of the QT c interval (Fig. 3 ). Polymorphic ventricular tachycardia in the setting of a prolonged QT c interval (QT c Ն460 msec) is commonly referred to as the syndrome of torsades de pointes. Since salvos or bursts of polymorphic ventricular tachycardia often precede the development of sustained arrhythmias, the distinction between nonsustained and sustained forms is less important. The mechanism of torsades de pointes is thought to be triggered activity secondary to early afterdepolarizations. A myriad of abnormalities are responsible for the acquired form of this syndrome, with drugs and electro-lyte abnormalities being the most common (the congenital form of long QT syndrome is beyond the scope of this discussion). Causes commonly encountered in the ICU include hypokalemia, hypomagnesemia, hypothermia, drugs, such as type I and III antiarrhythmics (quinidine, procainamide, sotalol), antibiotics (erythromycin, pentamidine, ketoconazole), antihistamines (terfenadine, astemizole), and tricyclic antidepressants. Bradycardia with heart block and intracranial hemorrhage are other causes not related to drug therapy. Frequently, the etiology is multifactorial. Recent data show that some patients have an underlying genetic predisposition to developing QT c prolongation on exposure to appropriate agents (25) , further highlighting the relationship between underlying substrate and environmental influences in arrhythmogenesis.
The first priority in the management of torsades de pointes is identifying and withdrawing the offending agent in addition to correcting any coexistent electrolyte abnormalities. Regardless of the serum level, intravenous magnesium should be administered promptly. If the arrhythmia recurs, isoproterenol infusion or rapid ventricular pacing must be initiated. Recognition of torsades de pointes is crucial, because inappropriate therapy with antiarrhythmic drugs that further prolong the QT c interval could be catastrophic. The syndrome should be suspected when pause-dependent initia-tion of polymorphic ventricular tachycardia is observed. This feature may suggest the diagnosis in situations where marked QT c prolongation is absent (11, 26) . The long-term management of polymorphic ventricular tachycardia in the setting of acquired long QT c should be focused on avoiding any potential offending agents. The prognosis in these patients is good, and no long-term therapy is needed.
Polymorphic ventricular tachycardia in the absence of QT c prolongation should alert the physician to ischemia as the most likely cause. Polymorphic ventricular tachycardia may occur secondary to marked electrolyte disturbances or severe heart failure, as well. It should be emphasized that (at least in the out-ofhospital survivor of cardiac arrest) modest degrees of hypokalemia and hypomagnesemia are common, and thus, caution should be exercised before attributing polymorphic ventricular tachycardia or ventricular fibrillation to electrolyte abnormalities, unless profound deficiencies are present (27) . The substrate for the development of polymorphic ventricular tachycardia in the absence QT c prolongation is most commonly ischemic heart disease and left ventricular systolic dysfunction. In the setting of an acute myocardial infarction, polymorphic ventricular tachycardia/ventricular fibrillation in the early phase (Ͻ48 hrs) does not predict a worse prognosis if patients survive to hospital discharge (28) . Consequently, polymorphic ventricular tachycardia/ ventricular fibrillation in the early phase of an acute MI does not warrant additional evaluation or treatment. On the other hand, polymorphic ventricular tachycardia/ventricular fibrillation in the late phase of myocardial infarction carries a poor prognosis. Late polymorphic ventricular tachycardia/ventricular fibrillation characteristically occurs in patients in whom the MI has been complicated by severe heart failure or cardiogenic shock, and as such, the prognosis is usually determined by the hemodynamic status rather than the presence of arrhythmias. In selected patients, electrophysiology study or implantable cardioverter-defibrillator therapy may be considered. In the absence of myocardial infarction, acute ischemia remains a common cause of polymorphic ventricular tachycardia/ventricular fibrillation. Withdrawal of catecholamines (if tolerated) and anti-ischemic therapy with ␤ blockers must be considered. In patients with severe coronary artery disease, revascularization or intra-aortic balloon counterpulsation may be required. If these measures are contraindicated because of critical illness, pharmacologic therapy with intravenous lidocaine or amiodarone may be used. Management of recurrent polymorphic ventricular tachycardia in the setting of critical illness is often very difficult. Decisions on revascularization must be based on the frequency and duration of polymorphic ventricular tachycardia, the relative contribution of primary ischemia vs. other proarrhythmic factors, and the risks of the intervention. Similar to the survivor of out-ofhospital cardiac arrest from ventricular fibrillation, the risk of recurrent polymorphic ventricular tachycardia in these patients is high and their long-term prognosis is poor. The Antiarrhythmics Versus Implantable Defibrillator Trial, Canadian Implantable Defibrillator Study, and Cardiac Arrest Study in Hamburg enrolled patients with resuscitated ventricular fibrillation and found a survival benefit with implantable cardioverterdefibrillator therapy. Of note, the Antiarrhythmics Versus Implantable Defibrillator Trial included a substantial number of patients with in-hospital cardiac arrest. Therefore, all patients with polymorphic ventricular tachycardia/ventricular fibrillation in the absence of long QT c or a reversible factor of sufficient magnitude to explain the arrhythmia must have an evaluation of left ventricular function and coronary artery disease. Ischemia should be treated, and most patients, particularly those with left ventricular systolic dysfunction, should have an implantable car-dioverter-defibrillator placed if there are no contraindications.
